All Access

Health Tech Deals

Health Tech Deals Alerts

Alert

Standard

Health Tech Deals Thought Bubble

Thought Bubble

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

detroit

columbus

austin

kansas-city

dallas

atlanta

washington-dc

nw-arkansas

boulder

chicago

indianapolis

nashville

richmond

houston

san-francisco

seattle

colorado-springs

boston

des-moines

salt-lake-city

philadelphia

denver

phoenix

new-orleans

miami

twin-cities

huntsville

raleigh

san-antonio

portland

san-diego

tampa-bay

cleveland

pittsburgh

axios-local

axios-pro

axios-live

the-axios-show

The big picture: Insiders are gearing up for more dealmaking in the approximately $500 billion market, as companies eye GLP-1s, lab testing and biological age calculators.

Context: Longevity has bled into treatments for menopause, hormone replacement therapy, weight loss and anti-aging.

"The list goes on and on, depending on how broadly you define the market and what you as a consumer define as your longevity concerns," says Beth Mosier, West Monroe's director of health care M&A.

Case in point: Weight loss app Noom has "always been kind of thinking down the road of expanding more forcefully into the longevity space," says CEO Geoff Cook.

The company leverages virtual currency as rewards and gamifying well-being metrics for users, hoping to position itself as a Duolingo for health, says Cook.

What's next: Deeper integration with users' data — whether it be from wearables or medical records — is already in the works. Additional evaluations such as biomarker tests and biological age tools could also further come into focus next year.

"A lot of these companies now do blood work, and I think at the end of the day, people are going to try to build this health operating system that takes it all in," says longevity startup Hundred Health CEO Tyler Smith.

Next year's winners won't be selling supplements or PDF reports — they'll be delivering measurable, repeatable signals clinicians can take action on, says Hjalmar Nilsonne, CEO of full-body scan company Neko Health.

What we're watching: Oura, the smart ring maker most recently valued at $11 billion, is a much-anticipated IPO candidate — though CEO Tom Hale told CNBC last month there are no updates on listing plans.

The company has made several buys already and has been cited as a logical consolidator, but Hale tells Axios Pro that Oura is focusing on strategic partnerships.

State of play: A bevy of companies are flush with new capital and offerings — though they're staying mum on any plans to be acquisitive.

Function Health raised a $298 million Series B funding round in November that valued it at $2.5 billion. The longevity startup also bought Ezra, a company that specializes in whole-body MRI scanning, in May.

Neko Health raised a $260 million Series B round at a $1.8 billion valuation in January.

In May, Midi Health launched its longevity offering designed specifically for women — and covered by payors. The company followed it up with a $50 million Series C raise in October.

The bottom line: Living longer and cutting costs is the one thing in health care all stakeholders can agree on, Mosier says.

Why longevity companies will keep surging into 2026

Insiders are gearing up for even more activity in the approximately $500 billion market.

Illustration of an hourglass overflowing with sand.

Longevity&#x27;s allure isn&#x27;t fading in 2026.The big picture: Insiders are gearing up for more dealmaking in the approximately <a class="gtmContentClick" data-vars-link-text="$500 billion" data-vars-click-url="https://www.mckinsey.com/industries/consumer-packaged-goods/our-insights/future-of-wellness-trends" data-vars-content-id="ab7109b0-e076-4709-880e-53a0991901da" data-vars-headline="Why longevity companies will keep surging into 2026" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.mckinsey.com/industries/consumer-packaged-goods/our-insights/future-of-wellness-trends" target="_blank">$500 billion</a> market, as companies eye GLP-1s, lab testing and biological age calculators.

Why longevity companies will keep surging into 2026

What to read next